In a filing, Idexx Laboratories, Inc revealed its Director SZOSTAK M ANNE unloaded Company’s shares for reported $0.65 million on May 21 ’25. In the deal valued at $512.34 per share,1,260 shares were sold. As a result of this transaction, SZOSTAK M ANNE now holds 1,801 shares worth roughly $1.23 million.
Then, SZOSTAK M ANNE sold 1,046 shares, generating $537,372 in total proceeds. Upon selling the shares at $513.74, the Director now owns 262 shares.
Before that, SZOSTAK M ANNE bought 1,260 shares. Idexx Laboratories, Inc shares valued at $651,621 were divested by the Director at a price of $517.16 per share.
Jefferies initiated its Idexx Laboratories, Inc [IDXX] rating to a Buy in a research note published on July 01, 2025; the price target was $625. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who began to cover the stock in early December with a ‘”an Outperform”‘ rating. BTIG Research began covering IDXX with “Buy” recommendation on July 25, 2024. Piper Sandler revised its rating on January 30, 2024. It rated IDXX as “a Neutral” which previously was an “an Overweight”.
Price Performance Review of IDXX
On Monday, Idexx Laboratories, Inc [NASDAQ:IDXX] saw its stock jump 27.49% to $682.78. Over the last five days, the stock has gained 20.53%. Idexx Laboratories, Inc shares have risen nearly 43.41% since the year began. Nevertheless, the stocks have risen 65.15% over the past one year.
How much short interest is there in Idexx Laboratories, Inc?
A steep rise in short interest was recorded in Idexx Laboratories, Inc stocks on 2025-07-15, growing by 0.1 million shares to a total of 2.64 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 2.54 million shares. There was a rise of 3.97%, which implies that there is a positive sentiment for the stock.
